Tom Y. Lee

This profile gathers the share dealings of Tom Y. Lee in Pure Bioscience, Inc., where the filings describe the role as chief executive. In total, 41 filings cover trades dated from 24 October 2014 to 15 December 2022.

In open-market terms, that means 21 purchases worth €1.9M on one side and 1 sale worth €14k on the other. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 13 share grants and 3 option exercises. Since January 2022: 4 purchases and no sales on the market.

Half of the purchases are above €22k and half below. Of 13 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 19 December 2022, reports an open-market purchase of €6,135 in Pure Bioscience, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.